Springworks Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio
Springworks Therapeutics (US): 3 reconciled FDA prescription therapies, $39.9M 2024 CMS Part D & Medicaid spend, and $34,650 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 3 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | 2043-01-01 |
| 2024 CMS Total Public Spend | $39.9M |
| 2024 Medicare Part D Spend | $20.0M |
| 2024 Medicaid Spend | $19.9M |
| California HCAI SB 17 Filings | Specialty launch notice ($34,650 intro WAC) |